SK pharmteco is deploying $100 million to reinforce and expand capabilities across its viral vector business. Primarily, this concerns the company’s centers of excellence in King of Prussia, Pa., and Corbeil-Essones, France.

As biopharma companies develop diverse pipelines—established therapeutics to advanced therapies—SK pharmteco says being a versatile CDMO is critical.

SK pharmteco – A Three-Business-Unit Model

The funding commitment, SK pharmteco says, both supports strategic initiatives in viral vectors and reaffirms the company’s long-term growth strategy. The company wishes to sharpen its strategy to give pharmaceutical and biotechnology partners financial strength, technical rigor, and operational infrastructure.

According to SK pharmteco, these elements are necessary for long-term success as the company advances each of three business units. These comprise not only viral vectors, but also small molecules and peptides. SK pharmteco says its reinforcement in viral vectors is synchronized with the expansion of its small molecule and peptide businesses.

Viral Vector Enhancements

To that end, the focus of the investment in the Pennsylvania and France sites is operational excellence. SK pharmteco wants to further mature its quality systems, optimize process performance, and advance tech transfer, while enabling global innovation.

SK pharmteco CEO Joerg Ahlgrimm offered some of his thoughts on the funding commitment.

“Our strategy is built on the strength of three essential business units: small molecules, peptides, and viral vectors,” Ahlgrimm said. “As the industry evolves, our partners need a CDMO that combines specialized expertise, technical sophistication, and operational reliability across modalities. This commitment supports [strengthening] our viral vector business while advancing the broader capabilities, quality, and commercial readiness that customers expect.”